Private company

PLx Pharma Winddown Corp.

American pharmaceutical preparations company, incorporated in Delaware.

Last updated Oct 18, 2026.

Overview

IndustryPharmaceutical Preparations
HeadquartersDE
Incorporated inDE²
Business address9 Fishers Lane, Suite E, Sparta, Nj 07871²
Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

41.5%Gross margin³

-497.0%Operating margin³

-562.0%Net margin³

27260.0%Revenue growth, 2021³

-129.3%Return on equity³

Where the money goes

Where each dollar of revenue went, fiscal 2021

Selling, general and admin

Cost of revenue10¢$4.8M
Research and development9¢$4.2M
Selling, general and admin82¢$40.0M

Out of $8.2M in revenue.³ The company lost money this year.

Financial statements

Revenue⁴⁵⁶⁷³$8.2M in 2021

Gross profit³$3.4M in 2021+11243% since 2020

Operating income⁴⁵⁶⁸⁷³-$40.8M in 2021+117% since 2015

Net income⁴⁵⁶⁸⁷³-$46.1M in 2021+146% since 2015

Fiscal year	2015	2016	2017	2018	2019	2020	2021
Revenue	$0⁴	$20.0K⁵	$778.7K⁶	$753.1K⁶	$565.5K⁷	$30.0K³	$8.2M³
Cost of revenue						$0³	$4.8M³
Gross profit						$30.0K³	$3.4M³
Research and development		$78.7K⁵	$4.2M⁶	$3.9M⁸	$4.7M⁷	$4.3M³	$4.2M³
Selling, general and admin						$9.2M³	$40.0M³
Operating income	-$18.8M⁴	-$4.8M⁵	-$15.8M⁶	-$11.0M⁸	-$14.2M⁷	-$13.5M³	-$40.8M³
Income tax	$0¹¹		-$920.0K⁶			$0³	$0³
Net income	-$18.7M⁴	-$4.9M⁵	-$15.3M⁶	$896.5K⁸	-$20.5M⁷	-$15.2M³	-$46.1M³
Earnings per share			-$2.19⁶	$0.10⁸	-$3.84⁷	-$1.74⁷
Earnings per share (diluted)			-$2.19⁶	$0.10⁸	$8,916,190.00⁷	$9,714,951.00⁷

Total assets⁴⁵⁶⁸⁷³$76.6M in 2021+136% since 2015

Total liabilities⁴⁵⁶⁸⁷³$25.0M in 2021+1454% since 2015

Shareholders’ equity⁵⁶⁸⁷³$35.7M in 2021+31143% since 2015

Cash⁵⁶⁸⁷³$69.4M in 2021+75608% since 2015

Long-term debt⁶⁸⁷$622.3K in 2019−91% since 2017

Fiscal year	2015	2016	2017	2018	2019	2020	2021
Cash	$91.7K⁵	$59.3K⁶	$24.4M⁸	$14.3M⁸	$14.0M⁷	$22.4M³	$69.4M³
Current assets	$32.4M⁴	$189.9K⁵	$25.7M⁶	$14.9M⁸	$14.3M⁷	$23.0M³	$73.5M³
Total assets	$32.4M⁴	$616.5K⁵	$28.8M⁶	$18.4M⁸	$18.5M⁷	$26.6M³	$76.6M³
Current liabilities		$2.7M⁵	$1.8M⁶	$4.7M⁸	$6.1M⁷	$3.5M³	$11.9M³
Long-term debt			$6.9M⁶	$4.3M⁸	$622.3K⁷
Total liabilities	$1.6M⁴	$2.9M⁵	$24.2M⁶	$11.9M⁸	$16.9M⁷	$16.2M³	$25.0M³
Shareholders’ equity	$114.2K⁵	-$2.3M⁶	$4.6M⁸	$6.4M⁷	-$12.1M³	-$10.9M³	$35.7M³
Shares outstanding	10.3M shares⁴	4.4M shares⁵	8.7M shares⁶	8.7M shares⁸	9.2M shares⁷	13.9M shares³	27.5M shares³

Cash from operations⁵⁶⁸⁷³-$32.1M in 2021+1674% since 2016

Capital spending⁶⁸⁷$102.0K in 2020−81% since 2017

Free cash flow⁶⁸⁷³-$12.3M in 2020−11% since 2017

Fiscal year	2016	2017	2018	2019	2020	2021
Cash from operations	-$1.8M⁵	-$13.3M⁶	-$9.5M⁸	-$12.7M⁷	-$12.2M³	-$32.1M³
Capital spending		$537.6K⁶	$654.9K⁸	$241.7K⁷	$102.0K⁷
Free cash flow		-$13.8M	-$10.2M	-$12.9M	-$12.3M

Compare PLx Pharma Winddown Corp. with another company

Leadership

Who has led PLx Pharma Winddown Corp., and when. Pick a name to see everywhere that person has worked.

Chief executive

Chair

President

Chief financial officer

Chief operating officer

Gary L. Mossman2017

201520202025

Chief executive officerNatasha Giordano Apr 20, 2017 to Mar 16, 2022¹²
Chief executive officerDavid P. Luci Mar 12, 2014 to Jan 21, 2016¹³
ChairMichael J. Valentino Apr 20, 2017 to Feb 24, 2022¹⁴
ChairRobert J. Deluccia Mar 12, 2014 to Apr 20, 2017¹⁵
PresidentNatasha Giordano Apr 20, 2017 to Apr 20, 2017¹²
PresidentDavid P. Luci Mar 12, 2014 to Jan 21, 2016¹³
Chief financial officerDavid Emerson Jorden Apr 20, 2017 to Jun 16, 2017¹⁶
Chief financial officerRita M. O'Connor Jul 11, 2017 to Mar 16, 2022¹⁷
Chief operating officerGary L. Mossman Apr 20, 2017 to Jun 16, 2017¹⁸

Board members and other officers (14)

Chief Medical OfficerEfthymios Deliargyris Aug 31, 2018 to Mar 24, 2020¹⁹
VP, Sales and MarketingMichael J. Dillon May 5, 2017 to May 5, 2017²⁰
Chief Accounting Officer, TreaRobert G. Shawah Mar 12, 2014 to Apr 20, 2017²¹
Board memberAnthony Bartsh Mar 18, 2019 to Mar 18, 2019²²
Board memberGary S. Balkema Apr 20, 2017 to Feb 24, 2022²³
Board memberJohn Hadden Apr 20, 2017 to Feb 24, 2022²⁴
Board memberKirk K. Calhoun Apr 20, 2017 to Nov 20, 2020²⁵
Board memberNatasha Giordano Apr 20, 2017 to Mar 16, 2022¹²
Board memberBarry Kagan Feb 3, 2015 to Apr 20, 2017²⁶
Board memberChris Coughlin Mar 12, 2014 to Mar 20, 2014²⁷
Board memberDavid P. Luci Mar 12, 2014 to Apr 21, 2017¹³
Board memberJack H. Dean Mar 12, 2014 to Apr 20, 2017²⁸
Board memberMichael E. Duffy Mar 12, 2014 to Apr 20, 2017²⁹
Board memberWilliam J. McSherry Jr. Mar 12, 2014 to Apr 20, 2017³⁰

Former names

PLx Pharma Inc.Feb 21, 2017 to May 2, 2023²
Dipexium Pharmaceuticals, Inc.Jan 21, 2014 to Apr 20, 2017²
Dipexium Pharmaceuticals, LLCJul 30, 2010 to Mar 13, 2014²

Timeline

Apr 20, 2017New chief executive Natasha Giordano becomes CEO¹²
Mar 12, 2014New chief executive David P. Luci becomes CEO¹³

Filings

46 filings to the SEC since October 2021: 2 annual reports, 4 quarterly reports, 21 major events, 9 insider forms, 5 large holders, 5 other. The latest 20:

Oct 18, 202315-12G EDGAR
Sep 20, 20238-K EDGAR
Aug 22, 20238-K EDGAR
Jul 21, 20238-K EDGAR
Jul 12, 20238-K EDGAR
Jul 7, 20238-K EDGAR
Jun 27, 20238-K EDGAR
May 26, 20238-K EDGAR
Apr 13, 20238-K EDGAR
Apr 12, 20238-K EDGAR
Apr 10, 20238-K EDGAR
Apr 6, 2023SC 13G EDGAR
Mar 8, 20238-K EDGAR
Feb 14, 2023SC 13G/A EDGAR
Feb 13, 20238-K EDGAR
Jan 20, 20238-K EDGAR
Nov 10, 202210-Q EDGAR
Nov 10, 20228-K EDGAR
Oct 7, 20228-K EDGAR
Sep 29, 2022DEFA14A EDGAR

The 46 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 5 such filings since October 2021:

Apr 6, 2023SC 13G
Feb 14, 2023SC 13G/A
Feb 16, 2022SC 13G/A
Feb 14, 2022SC 13G/A
Feb 11, 2022SC 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARPLx Pharma Winddown Corp. filings on SEC EDGAR
2
SEC EDGARPLx Pharma Winddown Corp. filings on SEC EDGAR
3
SEC EDGARPLx Pharma Winddown Corp. 10-K for fiscal 2021
4
SEC EDGARPLx Pharma Winddown Corp. 10-K for fiscal 2015
5
SEC EDGARPLx Pharma Winddown Corp. 10-K for fiscal 2016
6
SEC EDGARPLx Pharma Winddown Corp. 10-K for fiscal 2017
7
SEC EDGARPLx Pharma Winddown Corp. 10-K for fiscal 2019
8
SEC EDGARPLx Pharma Winddown Corp. 10-K for fiscal 2018
9
SEC EDGARPLx Pharma Winddown Corp. 10-Q for fiscal 2022
10
SEC EDGARPLx Pharma Winddown Corp. 10-Q for fiscal 2022
11
SEC EDGARPLx Pharma Winddown Corp. 10-K for fiscal 2015
12
SEC EDGARNatasha Giordano, Chief executive officer
13
SEC EDGARDavid P. Luci, Chief executive officer
14
SEC EDGARMichael J. Valentino, Chair
15
SEC EDGARRobert J. Deluccia, Chair
16
SEC EDGARDavid Emerson Jorden, Chief financial officer
17
SEC EDGARRita M. O'Connor, Chief financial officer
18
SEC EDGARGary L. Mossman, Chief operating officer
19
SEC EDGAREfthymios Deliargyris, Chief Medical Officer
20
SEC EDGARMichael J. Dillon, VP, Sales and Marketing
21
SEC EDGARRobert G. Shawah, Chief Accounting Officer, Trea
22
SEC EDGARAnthony Bartsh, Board member
23
SEC EDGARGary S. Balkema, Board member
24
SEC EDGARJohn Hadden, Board member
25
SEC EDGARKirk K. Calhoun, Board member
26
SEC EDGARBarry Kagan, Board member
27
SEC EDGARChris Coughlin, Board member
28
SEC EDGARJack H. Dean, Board member
29
SEC EDGARMichael E. Duffy, Board member
30
SEC EDGARWilliam J. McSherry Jr., Board member